COVID-19 in hematopoietic stem cell transplant recipients during three years of the pandemic: a multicenter study in Brazil
Hematopoietic stem cell transplant (HSCT) recipients are at -increased risk for severe COVID-19. The aim of this study was to evaluate the burden of COVID-19 in a cohort of HSCT recipients. This retrospective study evaluated a cohort of adult hospitalized HSCT recipients diagnosed with COVID-19 in t...
Gespeichert in:
| Veröffentlicht in: | Revista do Instituto de Medicina Tropical de São Paulo 2024-01, Vol.66, p.e17-7 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 7 |
|---|---|
| container_issue | |
| container_start_page | e17 |
| container_title | Revista do Instituto de Medicina Tropical de São Paulo |
| container_volume | 66 |
| creator | Randi, Bruno Azevedo Higashino, Hermes Ryoiti Silva, Vinícius Ponzio da Salomão, Matias Chiarastelli Pignatari, Antonio Carlos Campos Abdala, Edson Vasques, Fabiana Silva, Celso Arrais Rodrigues da Silva, Roberto Luiz da Lazari, Carolina Dos Santos Levi, José Eduardo Xavier, Erick Menezes Côrtes, Marina Farrel Luna-Muschi, Alessandra Rocha, Vanderson Costa, Silvia Figueiredo |
| description | Hematopoietic stem cell transplant (HSCT) recipients are at -increased risk for severe COVID-19. The aim of this study was to evaluate the burden of COVID-19 in a cohort of HSCT recipients. This retrospective study evaluated a cohort of adult hospitalized HSCT recipients diagnosed with COVID-19 in two large hospitals in São Paulo, Brazil post-HSCT, from January 2020 to June 2022. The primary outcome was all-cause mortality. Of 49 cases, 63.2% were male with a median age of 47 years. Allogeneic-HSCT (51.2%) and autologous-HSCT (48.9%) patients were included. The median time from HSCT to COVID-19 diagnosis was 398 days (IQR: 1211-134), with 22 (44.8%) cases occurring within 12 months of transplantation. Most cases occurred during the first year of the pandemic, in non-vaccinated patients (n=35; 71.4%). Most patients developed severe (24.4%) or critical (40.8%) disease; 67.3% received some medication for COVID-19, primarily corticosteroids (53.0%). The probable invasive aspergillosis prevalence was 10.2%. All-cause mortality was 40.8%, 51.4% in non-vaccinated patients and 14.2% in patients who received at least one dose of the vaccine. In the multiple regression analyses, the variables mechanical ventilation (OR: 101.01; 95% CI: 8.205 - 1,242.93; p = 0.003) and chest CT involvement at diagnosis ≥50% (OR: 26.61; 95% CI: 1.06 - 664.26; p = 0.04) remained associated with all-cause mortality. Thus, HSCT recipients with COVID-19 experienced high mortality, highlighting the need for full vaccination and infection prevention measures. |
| doi_str_mv | 10.1590/S1678-9946202466017 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_sciel</sourceid><recordid>TN_cdi_scielo_journals_S0036_46652024000100603</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><scielo_id>S0036_46652024000100603</scielo_id><sourcerecordid>2973103119</sourcerecordid><originalsourceid>FETCH-LOGICAL-c423t-5e9e2250bc506cce13b26a55569ceeb3ad0a301f9eefa45ecfb180d19aaf030c3</originalsourceid><addsrcrecordid>eNpdUk1v1DAQtRCIlsIvQEKWuHBJGcexd80FlS0flSr1UOBqOc6k6yqxg-0gLf3zONqyajnZHr_3ZubNEPKawSkTCt5fM7laV0o1soa6kRLY6gk5PgSfPrgfkRcp3QKAAiWfkyO-FoytQR6Tu83Vz4vziinqPN3iaHKYgsPsLE0ZR2pxGGiOxqdpMD7TiNZNDn1OtJuj8zc0byMi3aGJiYa-PJFOxnc4OvuBGjrOQxErBIxFce52S6JP0fxxw0vyrDdDwlf35wn58eXz98236vLq68Xm7LKyTc1zJVBhXQtorQBpLTLe1tIIIaSyiC03HRgOrFeIvWkE2r4tvXVMGdMDB8tPyOleN1mHQ9C3YY6-JNTXAFzqYp1YHCz2MAAJvBA-7gnT3I7YLdVHM-gputHEnQ7G6cc_3m31TfitGRSzmxqKwrt7hRh-zZiyHl1avDQew5x0rVacAWdMFejb_6CH-jjIZgVScFFQfI-yMaQUsT9Uw0Av66DTMm39aB0K683DRg6cf_PnfwHeGa_h</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3064706535</pqid></control><display><type>article</type><title>COVID-19 in hematopoietic stem cell transplant recipients during three years of the pandemic: a multicenter study in Brazil</title><source>PubMed Central Open Access</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Randi, Bruno Azevedo ; Higashino, Hermes Ryoiti ; Silva, Vinícius Ponzio da ; Salomão, Matias Chiarastelli ; Pignatari, Antonio Carlos Campos ; Abdala, Edson ; Vasques, Fabiana ; Silva, Celso Arrais Rodrigues da ; Silva, Roberto Luiz da ; Lazari, Carolina Dos Santos ; Levi, José Eduardo ; Xavier, Erick Menezes ; Côrtes, Marina Farrel ; Luna-Muschi, Alessandra ; Rocha, Vanderson ; Costa, Silvia Figueiredo</creator><creatorcontrib>Randi, Bruno Azevedo ; Higashino, Hermes Ryoiti ; Silva, Vinícius Ponzio da ; Salomão, Matias Chiarastelli ; Pignatari, Antonio Carlos Campos ; Abdala, Edson ; Vasques, Fabiana ; Silva, Celso Arrais Rodrigues da ; Silva, Roberto Luiz da ; Lazari, Carolina Dos Santos ; Levi, José Eduardo ; Xavier, Erick Menezes ; Côrtes, Marina Farrel ; Luna-Muschi, Alessandra ; Rocha, Vanderson ; Costa, Silvia Figueiredo</creatorcontrib><description>Hematopoietic stem cell transplant (HSCT) recipients are at -increased risk for severe COVID-19. The aim of this study was to evaluate the burden of COVID-19 in a cohort of HSCT recipients. This retrospective study evaluated a cohort of adult hospitalized HSCT recipients diagnosed with COVID-19 in two large hospitals in São Paulo, Brazil post-HSCT, from January 2020 to June 2022. The primary outcome was all-cause mortality. Of 49 cases, 63.2% were male with a median age of 47 years. Allogeneic-HSCT (51.2%) and autologous-HSCT (48.9%) patients were included. The median time from HSCT to COVID-19 diagnosis was 398 days (IQR: 1211-134), with 22 (44.8%) cases occurring within 12 months of transplantation. Most cases occurred during the first year of the pandemic, in non-vaccinated patients (n=35; 71.4%). Most patients developed severe (24.4%) or critical (40.8%) disease; 67.3% received some medication for COVID-19, primarily corticosteroids (53.0%). The probable invasive aspergillosis prevalence was 10.2%. All-cause mortality was 40.8%, 51.4% in non-vaccinated patients and 14.2% in patients who received at least one dose of the vaccine. In the multiple regression analyses, the variables mechanical ventilation (OR: 101.01; 95% CI: 8.205 - 1,242.93; p = 0.003) and chest CT involvement at diagnosis ≥50% (OR: 26.61; 95% CI: 1.06 - 664.26; p = 0.04) remained associated with all-cause mortality. Thus, HSCT recipients with COVID-19 experienced high mortality, highlighting the need for full vaccination and infection prevention measures.</description><identifier>ISSN: 1678-9946</identifier><identifier>ISSN: 0036-4665</identifier><identifier>EISSN: 1678-9946</identifier><identifier>DOI: 10.1590/S1678-9946202466017</identifier><identifier>PMID: 38511806</identifier><language>eng</language><publisher>Brazil: Instituto de Medicina Tropical de Sao Paulo</publisher><subject>Brief Communication ; TROPICAL MEDICINE</subject><ispartof>Revista do Instituto de Medicina Tropical de São Paulo, 2024-01, Vol.66, p.e17-7</ispartof><rights>2024. This work is published under https://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>This work is licensed under a Creative Commons Attribution 4.0 International License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c423t-5e9e2250bc506cce13b26a55569ceeb3ad0a301f9eefa45ecfb180d19aaf030c3</cites><orcidid>0000-0003-1925-4855 ; 0000-0002-6312-6669 ; 0000-0003-1087-752X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10946420/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10946420/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38511806$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Randi, Bruno Azevedo</creatorcontrib><creatorcontrib>Higashino, Hermes Ryoiti</creatorcontrib><creatorcontrib>Silva, Vinícius Ponzio da</creatorcontrib><creatorcontrib>Salomão, Matias Chiarastelli</creatorcontrib><creatorcontrib>Pignatari, Antonio Carlos Campos</creatorcontrib><creatorcontrib>Abdala, Edson</creatorcontrib><creatorcontrib>Vasques, Fabiana</creatorcontrib><creatorcontrib>Silva, Celso Arrais Rodrigues da</creatorcontrib><creatorcontrib>Silva, Roberto Luiz da</creatorcontrib><creatorcontrib>Lazari, Carolina Dos Santos</creatorcontrib><creatorcontrib>Levi, José Eduardo</creatorcontrib><creatorcontrib>Xavier, Erick Menezes</creatorcontrib><creatorcontrib>Côrtes, Marina Farrel</creatorcontrib><creatorcontrib>Luna-Muschi, Alessandra</creatorcontrib><creatorcontrib>Rocha, Vanderson</creatorcontrib><creatorcontrib>Costa, Silvia Figueiredo</creatorcontrib><title>COVID-19 in hematopoietic stem cell transplant recipients during three years of the pandemic: a multicenter study in Brazil</title><title>Revista do Instituto de Medicina Tropical de São Paulo</title><addtitle>Rev Inst Med Trop Sao Paulo</addtitle><description>Hematopoietic stem cell transplant (HSCT) recipients are at -increased risk for severe COVID-19. The aim of this study was to evaluate the burden of COVID-19 in a cohort of HSCT recipients. This retrospective study evaluated a cohort of adult hospitalized HSCT recipients diagnosed with COVID-19 in two large hospitals in São Paulo, Brazil post-HSCT, from January 2020 to June 2022. The primary outcome was all-cause mortality. Of 49 cases, 63.2% were male with a median age of 47 years. Allogeneic-HSCT (51.2%) and autologous-HSCT (48.9%) patients were included. The median time from HSCT to COVID-19 diagnosis was 398 days (IQR: 1211-134), with 22 (44.8%) cases occurring within 12 months of transplantation. Most cases occurred during the first year of the pandemic, in non-vaccinated patients (n=35; 71.4%). Most patients developed severe (24.4%) or critical (40.8%) disease; 67.3% received some medication for COVID-19, primarily corticosteroids (53.0%). The probable invasive aspergillosis prevalence was 10.2%. All-cause mortality was 40.8%, 51.4% in non-vaccinated patients and 14.2% in patients who received at least one dose of the vaccine. In the multiple regression analyses, the variables mechanical ventilation (OR: 101.01; 95% CI: 8.205 - 1,242.93; p = 0.003) and chest CT involvement at diagnosis ≥50% (OR: 26.61; 95% CI: 1.06 - 664.26; p = 0.04) remained associated with all-cause mortality. Thus, HSCT recipients with COVID-19 experienced high mortality, highlighting the need for full vaccination and infection prevention measures.</description><subject>Brief Communication</subject><subject>TROPICAL MEDICINE</subject><issn>1678-9946</issn><issn>0036-4665</issn><issn>1678-9946</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpdUk1v1DAQtRCIlsIvQEKWuHBJGcexd80FlS0flSr1UOBqOc6k6yqxg-0gLf3zONqyajnZHr_3ZubNEPKawSkTCt5fM7laV0o1soa6kRLY6gk5PgSfPrgfkRcp3QKAAiWfkyO-FoytQR6Tu83Vz4vziinqPN3iaHKYgsPsLE0ZR2pxGGiOxqdpMD7TiNZNDn1OtJuj8zc0byMi3aGJiYa-PJFOxnc4OvuBGjrOQxErBIxFce52S6JP0fxxw0vyrDdDwlf35wn58eXz98236vLq68Xm7LKyTc1zJVBhXQtorQBpLTLe1tIIIaSyiC03HRgOrFeIvWkE2r4tvXVMGdMDB8tPyOleN1mHQ9C3YY6-JNTXAFzqYp1YHCz2MAAJvBA-7gnT3I7YLdVHM-gputHEnQ7G6cc_3m31TfitGRSzmxqKwrt7hRh-zZiyHl1avDQew5x0rVacAWdMFejb_6CH-jjIZgVScFFQfI-yMaQUsT9Uw0Av66DTMm39aB0K683DRg6cf_PnfwHeGa_h</recordid><startdate>20240101</startdate><enddate>20240101</enddate><creator>Randi, Bruno Azevedo</creator><creator>Higashino, Hermes Ryoiti</creator><creator>Silva, Vinícius Ponzio da</creator><creator>Salomão, Matias Chiarastelli</creator><creator>Pignatari, Antonio Carlos Campos</creator><creator>Abdala, Edson</creator><creator>Vasques, Fabiana</creator><creator>Silva, Celso Arrais Rodrigues da</creator><creator>Silva, Roberto Luiz da</creator><creator>Lazari, Carolina Dos Santos</creator><creator>Levi, José Eduardo</creator><creator>Xavier, Erick Menezes</creator><creator>Côrtes, Marina Farrel</creator><creator>Luna-Muschi, Alessandra</creator><creator>Rocha, Vanderson</creator><creator>Costa, Silvia Figueiredo</creator><general>Instituto de Medicina Tropical de Sao Paulo</general><general>Instituto de Medicina Tropical de São Paulo</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>CLZPN</scope><scope>COVID</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>M2P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>S0X</scope><scope>7X8</scope><scope>5PM</scope><scope>GPN</scope><orcidid>https://orcid.org/0000-0003-1925-4855</orcidid><orcidid>https://orcid.org/0000-0002-6312-6669</orcidid><orcidid>https://orcid.org/0000-0003-1087-752X</orcidid></search><sort><creationdate>20240101</creationdate><title>COVID-19 in hematopoietic stem cell transplant recipients during three years of the pandemic: a multicenter study in Brazil</title><author>Randi, Bruno Azevedo ; Higashino, Hermes Ryoiti ; Silva, Vinícius Ponzio da ; Salomão, Matias Chiarastelli ; Pignatari, Antonio Carlos Campos ; Abdala, Edson ; Vasques, Fabiana ; Silva, Celso Arrais Rodrigues da ; Silva, Roberto Luiz da ; Lazari, Carolina Dos Santos ; Levi, José Eduardo ; Xavier, Erick Menezes ; Côrtes, Marina Farrel ; Luna-Muschi, Alessandra ; Rocha, Vanderson ; Costa, Silvia Figueiredo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c423t-5e9e2250bc506cce13b26a55569ceeb3ad0a301f9eefa45ecfb180d19aaf030c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Brief Communication</topic><topic>TROPICAL MEDICINE</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Randi, Bruno Azevedo</creatorcontrib><creatorcontrib>Higashino, Hermes Ryoiti</creatorcontrib><creatorcontrib>Silva, Vinícius Ponzio da</creatorcontrib><creatorcontrib>Salomão, Matias Chiarastelli</creatorcontrib><creatorcontrib>Pignatari, Antonio Carlos Campos</creatorcontrib><creatorcontrib>Abdala, Edson</creatorcontrib><creatorcontrib>Vasques, Fabiana</creatorcontrib><creatorcontrib>Silva, Celso Arrais Rodrigues da</creatorcontrib><creatorcontrib>Silva, Roberto Luiz da</creatorcontrib><creatorcontrib>Lazari, Carolina Dos Santos</creatorcontrib><creatorcontrib>Levi, José Eduardo</creatorcontrib><creatorcontrib>Xavier, Erick Menezes</creatorcontrib><creatorcontrib>Côrtes, Marina Farrel</creatorcontrib><creatorcontrib>Luna-Muschi, Alessandra</creatorcontrib><creatorcontrib>Rocha, Vanderson</creatorcontrib><creatorcontrib>Costa, Silvia Figueiredo</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Latin America & Iberia Database</collection><collection>Coronavirus Research Database</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>SIRS Editorial</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>SciELO</collection><jtitle>Revista do Instituto de Medicina Tropical de São Paulo</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Randi, Bruno Azevedo</au><au>Higashino, Hermes Ryoiti</au><au>Silva, Vinícius Ponzio da</au><au>Salomão, Matias Chiarastelli</au><au>Pignatari, Antonio Carlos Campos</au><au>Abdala, Edson</au><au>Vasques, Fabiana</au><au>Silva, Celso Arrais Rodrigues da</au><au>Silva, Roberto Luiz da</au><au>Lazari, Carolina Dos Santos</au><au>Levi, José Eduardo</au><au>Xavier, Erick Menezes</au><au>Côrtes, Marina Farrel</au><au>Luna-Muschi, Alessandra</au><au>Rocha, Vanderson</au><au>Costa, Silvia Figueiredo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>COVID-19 in hematopoietic stem cell transplant recipients during three years of the pandemic: a multicenter study in Brazil</atitle><jtitle>Revista do Instituto de Medicina Tropical de São Paulo</jtitle><addtitle>Rev Inst Med Trop Sao Paulo</addtitle><date>2024-01-01</date><risdate>2024</risdate><volume>66</volume><spage>e17</spage><epage>7</epage><pages>e17-7</pages><issn>1678-9946</issn><issn>0036-4665</issn><eissn>1678-9946</eissn><abstract>Hematopoietic stem cell transplant (HSCT) recipients are at -increased risk for severe COVID-19. The aim of this study was to evaluate the burden of COVID-19 in a cohort of HSCT recipients. This retrospective study evaluated a cohort of adult hospitalized HSCT recipients diagnosed with COVID-19 in two large hospitals in São Paulo, Brazil post-HSCT, from January 2020 to June 2022. The primary outcome was all-cause mortality. Of 49 cases, 63.2% were male with a median age of 47 years. Allogeneic-HSCT (51.2%) and autologous-HSCT (48.9%) patients were included. The median time from HSCT to COVID-19 diagnosis was 398 days (IQR: 1211-134), with 22 (44.8%) cases occurring within 12 months of transplantation. Most cases occurred during the first year of the pandemic, in non-vaccinated patients (n=35; 71.4%). Most patients developed severe (24.4%) or critical (40.8%) disease; 67.3% received some medication for COVID-19, primarily corticosteroids (53.0%). The probable invasive aspergillosis prevalence was 10.2%. All-cause mortality was 40.8%, 51.4% in non-vaccinated patients and 14.2% in patients who received at least one dose of the vaccine. In the multiple regression analyses, the variables mechanical ventilation (OR: 101.01; 95% CI: 8.205 - 1,242.93; p = 0.003) and chest CT involvement at diagnosis ≥50% (OR: 26.61; 95% CI: 1.06 - 664.26; p = 0.04) remained associated with all-cause mortality. Thus, HSCT recipients with COVID-19 experienced high mortality, highlighting the need for full vaccination and infection prevention measures.</abstract><cop>Brazil</cop><pub>Instituto de Medicina Tropical de Sao Paulo</pub><pmid>38511806</pmid><doi>10.1590/S1678-9946202466017</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0003-1925-4855</orcidid><orcidid>https://orcid.org/0000-0002-6312-6669</orcidid><orcidid>https://orcid.org/0000-0003-1087-752X</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1678-9946 |
| ispartof | Revista do Instituto de Medicina Tropical de São Paulo, 2024-01, Vol.66, p.e17-7 |
| issn | 1678-9946 0036-4665 1678-9946 |
| language | eng |
| recordid | cdi_scielo_journals_S0036_46652024000100603 |
| source | PubMed Central Open Access; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Brief Communication TROPICAL MEDICINE |
| title | COVID-19 in hematopoietic stem cell transplant recipients during three years of the pandemic: a multicenter study in Brazil |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T10%3A57%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_sciel&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=COVID-19%20in%20hematopoietic%20stem%20cell%20transplant%20recipients%20during%20three%20years%20of%20the%20pandemic:%20a%20multicenter%20study%20in%20Brazil&rft.jtitle=Revista%20do%20Instituto%20de%20Medicina%20Tropical%20de%20S%C3%A3o%20Paulo&rft.au=Randi,%20Bruno%20Azevedo&rft.date=2024-01-01&rft.volume=66&rft.spage=e17&rft.epage=7&rft.pages=e17-7&rft.issn=1678-9946&rft.eissn=1678-9946&rft_id=info:doi/10.1590/S1678-9946202466017&rft_dat=%3Cproquest_sciel%3E2973103119%3C/proquest_sciel%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3064706535&rft_id=info:pmid/38511806&rft_scielo_id=S0036_46652024000100603&rfr_iscdi=true |